Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback